Discussing Baricitinib for Alopecia Areata

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Amy McMichael, MD

Key Takeaways

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Inflammatory cytokines like IFN-γ and TNF-α are key contributors to immune-mediated hair follicle destruction.
The chronicity of alopecia areata is linked to persistent immune dysregulation and genetic predisposition.

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment for severe alopecia areata (AA).

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Epidemiology Associated With Alopecia Areata

EP: 3.Common Comorbidities Associated With Alopecia Areata

EP: 4.Hallmark Symptoms Seen With Alopecia Areata

EP: 5.Psychosocial Impact of Alopecia Areata

EP: 6.Diagnosis of Alopecia Areata

EP: 7.Multimodal Care for Patients With Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata

EP: 10.Adherence to Alopecia Areata Therapies

EP: 11.Adverse Events Associated With Conventional Alopecia Areata Therapies

EP: 12.Exploring Guidelines for Alopecia Areata

EP: 13.Unmet Needs for the Management of Alopecia Areata

Now Viewing

EP: 14.Discussing Baricitinib for Alopecia Areata

EP: 15.Highlighting Deuruxolitinib for Alopecia Areata

EP: 16.Exploring Ritlecitinib for Alopecia Areata

EP: 17.Analyzing the Safety Data of JAK Inhibitors

EP: 18.SALT Scoring for Alopecia Areata

EP: 19.Rapid Therapeutic Effects Seen With a JAK Inhibitor

EP: 20.Future Treatment of Patients With Alopecia Areata

EP: 21.Final Takeaways From the Panelists

Video content above is prompted by the following:

McMichael: Baricitinib became the first systemic treatment for severe AA after the BRAVE-AA1 and BRAVE-AA2 phase 3 trials were released. What did the data show in terms of safety and efficacy that led to FDA approval in 2022?